ANGI-01 ALTERATION IN IMMUNE REGULATORY CELLS BEFORE AND AFTER TREATMENT BY STUPP REGIMEN WITH OR WITHOUT BEVACIZUMAB FOR GLIOBLASTOMA

BACKGROUND: In our previous study, bevacizumab (Bev), a humanized anti- vascular endothelial growth factor monoclonal antibody, downregulated the expression of programmed cell death-1 (PD-1)/programmed cell death ligand-1 (PD-L1) immune checkpoint molecules, suppressed the infiltration of immunosupp...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Neurooncol Adv
Hlavní autoři: Tanaka, Toshihide, Tamura, Ryota, Yamamoto, Yohei, Morimoto, Yukina, Teshigawara, Akihiko, Tochigi, Satoru, Hasegawa, Yuzuru, Takei, Jun, Akasaki, Yasuharu, Sasaki, Hikaru, Murayama, Yuichi
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2019
Témata:
Abstracts
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7213323/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/noajnl/vdz039.019
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky